What is Covidien Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Covidien's cash to debt ratio for the quarter that ended in Dec. 2014 was 0.36.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Covidien couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2014.
The historical rank and industry rank for Covidien's Cash-to-Debt or its related term are showing as below:
FRA:6COP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1 Med: 0.36 Max: No Debt
Current: 0.36
During the past 13 years, Covidien's highest Cash to Debt Ratio was No Debt. The lowest was 0.10. And the median was 0.36.
Covidien Cash-to-Debt Historical Data
The historical data trend for Covidien's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Covidien Cash-to-Debt Chart
|
Covidien Annual Data
|
|
Trend |
Sep05 |
Sep06 |
Sep07 |
Sep08 |
Sep09 |
Sep10 |
Sep11 |
Sep12 |
Sep13 |
Sep14 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.33 |
0.36 |
0.37 |
0.37 |
0.31 |
|
Covidien Quarterly Data
|
|
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
Dec14 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.32 |
0.24 |
0.24 |
0.31 |
0.36 |
Competitive Comparison of Covidien's Cash-to-Debt
For the Medical Instruments & Supplies subindustry, Covidien's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covidien's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covidien's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Covidien's Cash-to-Debt falls into.
Covidien Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Covidien's Cash to Debt Ratio for the fiscal year that ended in Sep. 2014 is calculated as:
Covidien's Cash to Debt Ratio for the quarter that ended in Dec. 2014 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covidien (FRA:6COP) Business Description
Traded in Other Exchanges
N/A
Address
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.
Covidien (FRA:6COP) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:6COP has been successfully added to your